Researchers At Eli Lilly And Company Provide A New Understanding Of How Estrogen May Impact Women

August 29, 1996

Indianapolis, IN -- Eli Lilly and Company researchers studying the mechanism of action of the investigational compound raloxifene have discovered a new pathway through which estrogen affects various organs, according to an article being published in Science. Their findings may have important physiological implications for women, particularly their skeletal and cardiovascular health.

For several decades, researchers have acknowledged the benefits of estrogen in protecting women from cardiovascular diseases, osteoporosis and, more recently, Alzheimer's disease. However, they have also warned against the potential increase in breast and uterine cancer. And throughout this period, they have searched for an explanation of how estrogen affects various organs of the body so differently.

"The research published in Science gives us a new way of looking at what estrogen is, what estrogen receptors are and how new compounds interact with them to provide potential benefits, such as prevention of osteoporosis and cardiovascular disease, without causing some unfavorable effects, such as possible increases in breast and/or uterine cancer," explained Michael B. Sporn, M.D., professor of pharmacology and medicine at Dartmouth Medical School.

"There are public health implications from this research that we don't even know about yet; cardiovascular diseases, neurodegenerative diseases and various types of cancer all may be affected. This research creates a window of opportunity, showing us that the old model is no longer adequate and providing opportunities to develop new compounds that more effectively target different organs," he added.

In studies conducted with raloxifene, a drug that counters estrogen action in the breast while mimicking it in the bone, the Lilly team, led by molecular biologist Na N. Yang, Ph.D., has discovered a possible explanation for how the same drug may cause different effects, depending on which tissue it is acting in, and how the natural hormone itself manages to adopt so many different guises, according to Science.

"The team has found a second major pathway by which estrogen can regulate body functions," explained John D. Termine, Ph.D., a vice president at Lilly Research Laboratories. "In important nonreproductive tissues, such as the bones, raloxifene communicates with genes in the cell nucleus through a different route than the one traced for estrogens in the breast and other reproductive tissues. This changes the playing field by highlighting the potential of these two different major gene activation pathways." He explained that the clinical impact of this research on the future health of women -- and even men -- could be substantial.

"Beyond showing how estrogen acts in the body, this study is among the first to review multiple pathways that play potential roles in estrogen activity," said Yang. "Perhaps in the future, we may confirm that there is some estrogen for reproduction and other estrogen for bone, the cardiovascular or the central nervous system. It gives us the hope of engineering a drug that will provide the benefits of estrogen without the side effects. This research is just the beginning in a revolutionary approach to health care for the more than 150 million women worldwide with osteoporosis."

Lilly is a global research-based pharmaceutical corporation headquartered in Indianapolis, Indiana, dedicated to creating and delivering superior health care solutions -- by combining pharmaceutical innovation, existing pharmaceutical technology, disease prevention and management and information technologies -- in order to provide customers worldwide with optimal clinical and economic outcomes.
This release contains forward-looking information regarding the potential medical benefits of the investigational compound raloxifene, based on research conducted to date. Clinical studies are ongoing to determine the safety and efficacy of raloxifene. As with any investigational compound, there can be no assurance that preliminary findings will be supported by full-scale clinical trials or that regulatory clearances will be obtained.

Eli Lilly and Company

Related Health Care Articles from Brightsurf:

Study evaluates new World Health Organization Labor Care Guide for maternity care providers
The World Health Organization developed the new Labor Care Guide to support clinicians in providing good quality, women-centered care during labor and childbirth.

Six ways primary care "medical homes" are lowering health care spending
New analysis of 394 U.S. primary care practices identifies the aspects of care delivery that are associated with lower health care spending and lower utilization of emergency care and hospital admissions.

Modifiable health risks linked to more than $730 billion in US health care costs
Modifiable health risks, such as obesity, high blood pressure, and smoking, were linked to over $730 billion in health care spending in the US in 2016, according to a study published in The Lancet Public Health.

Spending on primary care vs. other US health care expenditures
National health care survey data were used to assess the amount of money spent on primary care relative to other areas of health care spending in the US from 2002 to 2016.

MU Health Care neurologist publishes guidance related to COVID-19 and stroke care
A University of Missouri Health Care neurologist has published more than 40 new recommendations for evaluating and treating stroke patients based on international research examining the link between stroke and novel coronavirus (COVID-19).

Large federal program aimed at providing better health care underfunds primary care
Despite a mandate to help patients make better-informed health care decisions, a ten-year research program established under the Affordable Care Act has funded a relatively small number of studies that examine primary care, the setting where the majority of patients in the US receive treatment.

International medical graduates care for Medicare patients with greater health care needs
A study by a Massachusetts General Hospital research team indicates that internal medicine physicians who are graduates of medical schools outside the US care for Medicare patients with more complex medical needs than those cared for by graduates of American medical schools.

The Lancet Global Health: Improved access to care not sufficient to improve health, as epidemic of poor quality care revealed
Of the 8.6 million deaths from conditions treatable by health care, poor-quality care is responsible for an estimated 5 million deaths per year -- more than deaths due to insufficient access to care (3.6 million) .

Under Affordable Care Act, Americans have had more preventive care for heart health
By reducing out-of-pocket costs for preventive treatment, the Affordable Care Act appears to have encouraged more people to have health screenings related to their cardiovascular health.

High-deductible health care plans curb both cost and usage, including preventive care
A team of researchers based at IUPUI has conducted the first systematic review of studies examining the relationship between high-deductible health care plans and the use of health care services.

Read More: Health Care News and Health Care Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to